Table 1.
Comparison of clinical features of the five cases of acute promyelocytic leukemia with IRF2BP2-RARA fusion
| Originate country/Publish time | Age/ gender |
Regular blood test | Coagulant function |
Bone marrow morphology | Flow cytometry | Chromosome karyotype | IRF2BP2-RARA breakpoint | Induction treatment | Achieve CR | EFS after CR1 | Allogeneic HSCT | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| USA, 2015 | 19 y/ Female |
4.5×109/L Hb 91 g/L Plt 2×109/L |
PT 19.6 s APTT 46.3 s D-dimer >20 µg/mL FIB 60 mg/dL |
Classic APL morphology | Aberrant promyelocytic immunophenotype (no detail) | Diploid karyotype | Exon 2 in IRF2BP2 and intron 2 in the RARA | ARAT+AS2O3+igemtuzumab ozogamicin | Yes | 8 months | Yes | CR2 |
| Japan, 2016 | 68 y/ Female |
WBC 1.65×109/L Hb 82 g/L Plt 48×109/L |
Normal | Classic APL morphology | CD33+, CD34+, CD64+, CD117+, HLA-DR+, CD2-, CD7-, CD13-, CD19- | -X | Exon 1 in IRF2BP2 and exons 3–9 in RARA | ATRA+idarubucin+Arac+gemtuzumab ozogamicin | Yes | 10 months | No | Died |
| UK, 2016 | 37 y/ Male |
WBC 3.8×109/L Hb 125 g/L Plt 7×109/L |
FIB 138mg/dL D-dimer >20 µg/mL |
Classic APL morphology No Auer rods |
CD34, HLADR-, CD117+ weak, CD13+, CD33+, CD11b, CD15-, CD45+ weak, CD71-, CD56-. | Normal karyotype | Intron 1 in IRF2BP2 and intron 2 in RARA | ATRA only | Yes | Not known | No | CR1 |
| USA, 2018 | 34 y/ Male |
WBC 4.1×109/L Hb 93 g/L Plt 23×109/L |
D-dimer 37.21 mg/L | Classic APL morphology | CD13+, CD33+CD38 (dim)+, CD117+, MPO+, HLA-DR- | T(1;17)(q42;q21) | Extron 1 in IRF2BP2 and extron 3 in RARA | ATRA+idarubucin+Arac | Yes | 18 months | No | CR1 |
| China, 2019 | 32 y/ Female |
WBC 5.14109/L Hb 64 g/L Plt 33×109/L |
PT 14 s | Classic APL morphology | CD13+, CD33+, CD117+, CD64+, HLA-DR-, CD34- | -X | Intron 1 in IRF2BP2 and intron 2 in the RARA NRAS and BMP4 mutation were detected at relapse |
ARAT+ATO+DNR+Arac | Yes | 12 months | No | Died |